Published in Immunotherapy Weekly, November 8th, 2006
These data were presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, California.
"Treatment-experienced patients continue to respond to Aptivus after 2 years of therapy in the RESIST study," said Margaret Johnson, MD, clinical director, HIV/AIDS services, Royal Free Hospital, London, England. "As HIV-positive patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.